On April 13, 2023 Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported that two key industry opinion leaders and management will participate in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR-T Cell Therapy in Hematological Malignancies and Solid Tumors on Tuesday, April 18, 2023 at 1:30 p.m. EDT (Press release, Oncternal Therapeutics, APR 13, 2023, View Source [SID1234630091]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer & Co. Senior Research Biotech Analyst, Hartaj Singh, will moderate a discussion with:

Michael Wang, M.D., Endowed Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center
Angela Shen, M.D, Ph.D., Associate Professor, Medicine, Harvard Medical School Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital
James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer
Please contact your Oppenheimer & Co. institutional salesperson to participate in the call. Links to the replay will be accessible on the Events & Presentations page of the Investors section on the Company’s website at investor.oncternal.com, for at least 30 days after the event.